UK markets closed
  • NIKKEI 225

    26,165.59
    +638.22 (+2.50%)
     
  • HANG SENG

    26,588.20
    +102.00 (+0.39%)
     
  • CRUDE OIL

    44.82
    +1.76 (+4.09%)
     
  • GOLD FUTURES

    1,802.90
    -34.90 (-1.90%)
     
  • DOW

    30,032.03
    +440.76 (+1.49%)
     
  • BTC-GBP

    14,321.72
    +475.57 (+3.43%)
     
  • CMC Crypto 200

    380.43
    +10.68 (+2.89%)
     
  • ^IXIC

    12,034.19
    +153.55 (+1.29%)
     
  • ^FTAS

    3,633.35
    +51.07 (+1.43%)
     

Merus to Present at the Jefferies Virtual London Healthcare Conference

Merus N.V.
·1-min read

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 14:40 p.m. GMT/9:40 a.m. ET.

A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl/. An archived presentation will be available on the Merus website for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, www.merus.nl and https://twitter.com/MerusNV.

CONTACT: Investor and Media Inquiries: Jillian Connell Merus N.V. Investor Relations and Corporate Communications 617-955-4716 j.connell@merus.nl